Clinical trial
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis…
NCT00143273 · Ligand Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00143273 |
|---|---|
| Title | Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation |
| Official title | Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis (Placebo-Controlled, Multicenter, Double-Blind, Comparative Study) - Japanese Asian Dose Evaluation: JADE |
| Acronym | JADE |
| Lead sponsor | Ligand Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | lasofoxifene, Placebo, Lasofoxifene |
| Enrollment | 497 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Aug 10, 2011 |
| Countries | Japan, South Korea, Taiwan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: